Our study demonstrates that TFDP3 contributes to MDR pattern in MRD by suppressing E2F1-induced apoptosis, and targeting TFDP3 may provide a promising strategy for improving leukemia treatment and for overcoming DNA damage based chemoresistance in residual cancer. The gene discussed is TFDP3; the disease is leukemia.